Hans Lennart Rudolf Wigzell

CIK: 0001492766

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)1 (25.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SRPT

Sarepta Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

SRPT
Sarepta Therapeutics, Inc.
Jun 4, 2026
Award(A)
Direct
16.9K shares-
SRPT
Sarepta Therapeutics, Inc.
Mar 10, 2025
Award(A)
Direct
2.4K shares-
SRPT
Sarepta Therapeutics, Inc.
Dec 12, 2024
Exercise(M)
Direct
10.5K shares at avg. $13.71$144K
SRPT
Sarepta Therapeutics, Inc.
Dec 12, 2024
Sale(S)
Direct
10.5K shares at avg. $124.84$1.3M

		Type	Shares	Price		Ownership
Jun 4, 2026	SRPT Sarepta Therapeutics, Inc.	Award(A)	16,875	-	$0	Direct
Mar 10, 2025	SRPT Sarepta Therapeutics, Inc.	Award(A)	2,383	-	-	Direct
Dec 12, 2024	SRPT Sarepta Therapeutics, Inc.	Exercise(M)	10,500	$13.71	$143,955	Direct
Dec 12, 2024	SRPT Sarepta Therapeutics, Inc.	Sale(S)	10,500	$124.84	$1,310,820	Direct

1-4 of 4 transactions

About Wigzell Hans Lennart Rudolf

Wigzell Hans Lennart Rudolf (SEC CIK 0001492766) files insider reports with the SEC as Director of Sarepta Therapeutics, Inc. (SRPT).

Signal8 holds 3 ownership filings by Wigzell Hans Lennart Rudolf, all Form 4s, filed between Dec 16, 2024 and Jun 5, 2026. Those filings report 4 transactions, from Dec 12, 2024 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Wigzell Hans Lennart Rudolf's filings is in CAMBRIDGE, MA.

Recent filings by Wigzell Hans Lennart Rudolf

Jun 4, 2026: Grant or award of SRPT shares (Form 4, code A).
Mar 10, 2025: Grant or award of SRPT shares (Form 4, code A).
Dec 12, 2024: Option exercise of SRPT shares (Form 4, code M).
Dec 12, 2024: Open-market sale of SRPT shares (Form 4, code S).

Other insiders filing for Sarepta Therapeutics, Inc. (SRPT)

Wong Ryan Ho-Yan, Chief Financial Officer
Estepan Ian Michael, Chief Operating Officer
Rothfuss Cristin, EVP, General Counsel
Rodino-Klapac Louise, President, R&D and Tech Ops
SEVERINO MICHAEL, Chief Executive Officer
Boor Kathryn Jean, Director

How to read Form 4 transaction codes